Abstract: The aim of the present study was to analyze whether angiotensin II via the endocannabinoid system can induce gastric mucosal protection, since transactivation of cannabinoid CB1 receptors by angiotensin AT1 receptor in CHO cells was described. Experimental ulcer was induced by acidified ethanol given orally in male Wistar rats, CB1(+/+) wild type and CB1(-/-) knock out mice. The compounds were administered intracerebroventricularly. It was found, that 1./ Angiotensin II inhibited the ethanol-induced gastric lesions (11.9-191 pmol); the effect of angiotensin II (191 pmol) was inhibited by the CB1 receptor inverse agonist AM 251 (1.8 nmol) and the inhibitor of diacylglycerol lipase (DAGL), tetrahydrolipstatin (0.2 nmol). 2./ Angiotensin II exerted gastroprotection in wild type, but not in CB1(-/-) mice. 3./ The gastroprotective effect of angiotensin II (191 pmol) was reduced by atropine (1 mg/kg i.v.) and bilateral cervical vagotomy. In conclusion, stimulation of central angiotensin AT1 receptors via activation of cannabinoid CB1 receptors induces gastroprotection in a DAGL-dependent and vagus-mediated mechanism. 
Introduction
Cannabinoid receptors are a class of cell membrane receptors under the G proteincoupled receptor (GPCR) superfamily (Matsuda et al., 1990) . To date, two cannabinoid receptors have been identified by molecular cloning, CB 1 and CB 2 receptors (Howlett et al., 2002; Matsuda et al., 1990; Munro et al., 1993) , however the existence of additional CB receptors have also been proposed (Brown, 2007; Pacher et al., 2005; Ryberg et al., 2007) . Anandamide is a partial or full agonist of CB 1 receptors, depending on the tissue and biological response measured. Although it also binds to CB 2 receptors, it has very low efficacy and may act as an antagonist (Gonsiorek et al., 2000) . 2-AG acts as a full agonist and is the true natural ligand for both the CB 1 and the CB 2 receptors (Sugiura et al., 2006) .
Anandamide is produced from the membrane phospholipid N-arachidonoyl by a phospholipase C dependent process, while 2-AG is generated by diacylglycerol lipases (DAGLs) from diacylglycerol (DAG), which is produced during the signaling of Ca 2+ -mobilizing hormones, such as angiotensin II (Ang II) (Gyombolai et al., 2012) .
Mounting evidence suggest that cannabinoid receptors and their ligands are involved in numerous physiological and pathophysiological processes. In the central nervous system endocannabinoids can be produced postsynaptically, and act on presynaptic cannabinoid receptors as retrograde transmitters after they are translocated across the plasma membrane (Freund et al., 2003) . CB 1 receptors located presynaptically in several brain regions act as inhibitory retrograde signaling messengers at glutamatergic and GABAergic synapses, modulating the release of several neurotransmitters (Marsicano and Lutz, 1999; Piomelli, 2003) . Thus, the endocannabinoid system, through its neuromodulating activity, could be involved in several physiological functions, including memory processing, pain perception, locomotion and inflammation; additionally, its dysregulation could underlie several pathological conditions known to accompanying psychiatric disorders (Di Marzo, 2008) . In human therapy CB 1 receptor agonists (e.g. dronabinol) are already used against chemotherapy-induced nausea and vomiting, whereas CB 1 receptor antagonist rimonabant was introduced in the therapy of obesity (Pacher et al., 2006) , however, it was withdrawn from the market due to increased risk of suicide and depression (Steinberg and Cannon, 2007) . Nevertheless, specific targeting of peripheral CB 1 receptors ) and/or identification of the population, which is genetically resistant to the central side effects of rimonabant is still under consideration (Lazary et al., 2011) . Furthermore, modulating CB 1 receptor activity has therapeutic potential in a wide range of pathological conditions including mood and anxiety disorders, movement disorders, neuropathic pain, and multiple sclerosis, as well as cancer, cardiovascular diseases, obesity/metabolic syndrome and musculoskeletal disorders (Pacher et al., 2006) .
Increasing number of evidence suggest that CB 1 receptors may play a role in the modulation of gastrointestinal functions. Cannabinoids were shown to inhibit gastrointestinal motility (Izzo et al., 1999; Krowicki et al., 1999) , gastric acid secretion (Adami et al., 2002) and development of gastric mucosal lesions both in acid-dependent (Germano et al., 2001; Rutkowska and Fereniec-Goltbiewska, 2006 ) and acid-independent ulcer models (Shujaa et al., 2009 ). Accordingly, CB 1 receptors were identified in neurons of the enteric nervous system and in sensory terminals of vagal and spinal neurons, moreover, CB 1 receptors are also identified in the dorsal vagal complex: in the nucleus of the solitary tract (NTS) (Partosoedarso et al., 2003) , in the dorsal motor nucleus of vagus (DMNV) (Mackie, 2005) and prominently, in the area postrema (Mackie, 2005) .
Paracrine transactivation of CB 1 receptors by co-expressed type 1 angiotensin receptors (AT 1 ) in Chinese hamster ovary (CHO) cells was observed recently (Turu et al., 2007) . AT 1 receptor is a Gq-protein-coupled receptor. Activation of Gq/11 protein-coupled receptors results in activation of phospholipase C, which produces inositol-trisphosphate and diacylglycerol (DAG) from phosphatidylinositol (4,5)-bisphosphate. From DAG 2-AG is generated by diacylglycerol lipases (DAGLs). Accordingly, inhibition of DAGL in CHO cells interfered with the activation of CB 1 receptors (Turu et al., 2007) . The inhibitory effect of DAGL-inhibitor on these processes suggests that these actions are mediated mainly by 2-AG (Bisogno et al., 2005; Makara et al., 2005; Turu et al., 2009 ).
Since our recent findings showed that anandamide and synthetic cannabinoid analogues given centrally induced gastric mucosal protection by CB 1 receptor-mediated mechanism in the rat (Shujaa et al., 2009 ), the present study was designed to examine whether Ang II injected centrally can induce gastric mucosal defense in the rat and mouse via activation of the endocannabinoid system.
Here we show, that i.c.v. injection of both anandamide, 2-AG and Ang II induced gastric mucosal protection in the rat. The protective action of Ang II was likely to be mediated via activation of AT 1 and CB 1 receptors. The protective effect was decreased by tetrahydrolipstatin, an inhibitor of DAGL, the principle enzyme responsible for synthesis of 2-AG. Moreover, Ang II induced gastroprotective effect also in wild type mice, however, it failed to exert mucosal protective effect in CB 1 receptor deficient mice. Consequently, these data are the first in vivo evidence on the interaction between central AT 1 receptors and the endocannabinoid system in a DAGL-dependent mechanism.
Materials and methods

Animals
Experiments were carried out on male Wistar rats weighing 150-170 g received from the breeding colony of Semmelweis University and on CB1 receptor knockout (-/-, CB 1 R KO) and wild type (+/+, WT) C57BL/6J mice (21-25 g), kindly provided by Professor Andreas
Zimmer, University of Bonn (Zimmer et al., 1999) .
The animals were kept in a 12-hour light/dark cycle and under condition of controlled temperature. They were maintained on standard rat laboratory chow and tap water ad libitum.
All efforts were made to minimize animal suffering and to reduce the number of animals used in the experiments. All procedures conformed to the European Convention for the protection of vertebrate animals used for experimental and other scientific purposes. The study was approved by the Animal Ethics Committee of Semmelweis University, Budapest (permission number: 22.1/606/001/2010).
Experimental procedures
Gastric mucosal damage induced by acidified ethanol
After 24 h food deprivation 0.5 or 0.2 ml acidified ethanol (98 ml absolute ethanol + 2 ml concentrated HCl) was given orally to the rats and mice, respectively. 60 min later the animals were sacrificed, the stomachs were excised, opened along the greater curvature, rinsed with saline and examined for lesions. Total number of mucosal lesions was assessed in blinded manner by calculating the ulcer index based on a 0-4 scoring system described previously (Gyires, 1990) . The ulcer index was calculated as the total number of lesions multiplied by the respective severity factor. i.c.v.) to the lateral ventricle as described previously (Gyires et al., 2000) in a volume of 10 μl and 5 μl for rats and mice, respectively, 10 min before the ethanol challenge. To avoid a rapid increase of intracerebroventricular pressure the syringe was put into a special apparatus which allowed to inject the volume during optional (1 min 
Bilateral cervical vagotomy
Under pentobarbital anaesthesia (35 mg/kg intravenously), the cervical section of vagal nerves was exposed and bilateral cervical vagotomy was performed. Vagotomy slowed the respiration phase and enlarged the magnitude of respiration. Sham operated control rats had their vagus similarly exposed but the vagal trunks were not sectioned. The incisions were closed and all animals were allowed 3 hours recovery from operation.
Determination of gastric mucosal CGRP level
For determination of gastric mucosal level of calcitonin gene-related peptide (CGRP)
the rats were anesthetized with ether, the stomachs were removed and gastric mucosa was separated on a cooled plate. It was weighed and put in 1 ml cold distilled water, sonicated and stored at -80 ºC till the determination.
CGRP concentration was determined by radioimmunoassay (RIA) described previously (Németh et al., 1998) . For the specific RIA the antiserum (C1012) was raised in rabbit immunized with synthetic peptide conjugated to thyroglobulin by glutaraldehyde. The RIA tracer was mono-125 l-labelled peptide prepared by Németh et al. (2002) . Synthetic peptide was used as RIA standard ranging from 0 to 100 fmol/ml. The detection limit of the assay was 0.2 fmol/ml. This technique has proved to be specific, sensitive and valid for the measurement of neuropeptides in pharmacological research. CGRP concentration was calculated as the measured amount of peptide per wet tissue weight, expressed as fmol/mg.
Materials
Arachidonylethanolamide (anandamide), 2-arachidonoylglycerol (2-AG) and angiotensin II (Ang II) (human) were ordered from Ascent Scientific Ltd. (Bristol, UK). N-(Piperidin-1-yl)-
sulphate and pentobarbital sodium were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Candesartan was ordered from Toronto Research Chemicals (Toronto, Canada).
The stock solutions of anandamide (ethanol), 2-AG (acetonitrile) and AM-251 (DMSO) were diluted with saline. All the other drugs were dissolved in saline. Animals in the control groups received the drug solvents.
Statistical analysis
All data are presented as the means ± S.E.M. Statistical analysis of the data was evaluated by means of analysis of variance (ANOVA) followed by Newman-Keuls test for multiple comparisons. A probability value of less than 0.05 was considered statistically significant.
Results
The effect of anandamide and 2-AG on ethanol-induced gastric mucosal damage
and gastric mucosal level of CGRP.
Both anandamide and 2-AG in the doses of 2.9-115 and 3.3-26.4 nmol i.c.v., respectively, inhibited the development of ethanol-induced gastric mucosal lesions in a dosedependent manner (Fig. 1) , however, at higher dose (52.8 nmol) the protective effect of 2-AG was diminished. AM 251 (1.8 nmol i.c.v.), an inverse agonist of the CB 1 cannabinoid receptor, failed to affect the ethanol-induced gastric mucosal lesions, but reversed the gastroprotective effect of both anandamide (115 nmol i.c.v.) and 2-AG (6.6 nmol i.c.v.)
suggesting the involvement of central CB 1 cannabinoid receptors in the mucosal defensive processes (Fig. 2) .
The mucosal CGRP content decreased from 1.34 ± 0.1 fmol/mg to 0.25 ± 0.1 fmol/mg 
The effect of Ang II and its combination with candesartan, AM 251 and THL on
ethanol-induced gastric mucosal damage in the rat.
Ang II inhibited the ethanol-induced gastric mucosal lesions in a dose-dependent manner in the doses of 11.9-191 pmol i.c.v., however at higher dose (956 pmol) the mucosal protective effect was diminished (Fig. 4) 85.7 ± 7.9, Fig. 6 ). Fig. 7 illustrates representative macroscopic pictures of the protective effect of Ang II in wild type and in CB 1 receptor deficient mice.
The effect of bilateral cervical vagotomy and atropine on the gastroprotective action
of Ang II in the rat.
In sham operated rats Ang II (191 pmol) exerted a highly significant inhibition of ethanol-induced mucosal damage. Bilateral cervical vagotomy resulted in a slight, but not significant aggravation of gastric mucosal lesions compared to sham operated rats and reduced in a significant manner the Ang II-mediated gastric mucosal protective effect (Fig.   8A ). Atropine (1 mg/kg i.v.) failed to affect the ethanol-induced mucosal lesions, however, given 15 min before the i.c.v. administration of Ang II reduced in a significant manner the mucosal protective effect of Ang II, though did not abolish it (Fig. 8B) .
Discussion
G protein-coupled receptors mediate the effects of several neurotransmitters and neuromodulators on the target cells by stimulating G protein dependent and independent intracellular signaling pathways (DeWire et al., 2007; Hunyady and Catt, 2006; Lefkowitz, 2004) . Activation of Gq/11 protein-coupled receptors results in phospholipase C activation, which produces inositol-trisphosphate and DAG from phosphatidylinositol (4,5)-bisphosphate, and DAG can be converted to 2-AG by DAGL (Basavarajappa, 2007; Sugiura et al., 2006) .
It was recently shown that activation of the Gq/11-coupled angiotensin AT 1 receptor by angiotensin II resulted in activation of cannabinoid CB 1 receptors via a DAGL-dependent mechanism in CHO cells (Turu et al., 2007) . Namely, it was observed that inhibition of DAGL in these cells led to inhibition of the constitutive activity of CB 1 receptors, and similar results were obtained in HEK-293 cells (Turu et al., 2007 (Turu et al., , 2009 ). The transactivation of cannabinoid CB1 receptors by Ang II is supported by the finding that showed an inhibitory effect of AM 251, inverse agonist of CB 1 receptors, on the hypertensive effect of Ang II injected directly into the hypothalamic paraventricular nucleus of anaesthetized rats (Gyombolai et al., 2012) . Vice versa, AT 1 receptor expression may be directly regulated by CB 1 receptors, namely in cultured vascular smooth muscle cells inhibition of CB 1 receptor by rimonabant and AM 251 led to down-regulation of AT 1 receptor expression (Tiyerili et al., 2010) .
Cannabinoids are involved in numerous physiological and pathophysiological processes, and affect also gastrointestinal functions. For example they inhibit GI transit and motility in rats (Landi et al., 2002) , decrease the intragastric pressure and the pyloric contractility by activating CB 1 receptors (Krowicki et al., 1999) , tonically inhibit colonic propulsion (Pinto et al., 2002) and decrease GI transit in mice (Izzo et al., 2000) . CB 1 receptor agonists decreased the gastric acid secretion induced by pentagastrin given intravenously (Adami et al., 2002) , but i.c.v. injection of the synthetic non-selective agonist WIN 55,212-2 was ineffective in preventing the pentagastrin stimulated gastric acid secretion (Adami et al., 2004) . Cannabinoids have been shown to decrease the formation of experimental gastric ulcers as well. Tetrahydrocannabinol, for example, reduced mucosal damage induced by pylorus ligation (Sofia et al., 1978) and Cannabis sativa was effective against restraintinduced gastric ulcerations (De Souza et al., 1978) . Furthermore, anandamide reduced the gastric ulceration induced by water immersion and restraint stress (Dembinski et al., 2006) and WIN55,212-2 produced anti-ulcer effect in the cold/restraint stress model (Germano et al., 2001) . Moreover, the selective CB 1 receptor agonist ACEA (arachidonyl-2-chloroethylamide) significantly reduced gastric ulcer formation induced by aspirin (Rutkowska and Fereniec-Goltbiewska, 2006) .
The ulcer models used in the above experiments are gastric acid-dependent models, consequently, the inhibition of the mucosal lesions can be due either to inhibition of gastric acid secretion, or stimulation of gastric mucosal defense (or both). Moreover, since cannabinoids have been given peripherally, no conclusion could be drawn on the site of action, whether it is central or peripheral (or both), because cannabinoids are lipophilic compounds and easily pass the blood-brain barrier. We showed recently that anandamide and synthetic cannabinoids given i.c.v. exerted gastroprotective effect against the acidindependent ethanol ulcer model. Moreover, the mucosal protective effect of intravenously injected methanandamide was reversed by the centrally injected CB 1 receptor antagonist SR 141716A, indicating the role of central CB1 receptors in the gastroprotection (Shujaa et al., 2009 (Holzer et al., 1990 (Holzer et al., , 1991 . (Gyires et al., 2000) , nociceptin (Zádori et al., 2008) and substance P (Brancati et al., 2013) Ang II was initially described as a hormone of peripheral origin, the active end product of the renin-angiotensin system. The discovery of brain Ang II receptors located in neurons inside the blood brain barrier confirmed the existence of an endogenous brain Ang II system.
Classical actions of Ang II in the brain include the regulation of hormone formation and release, the control of sympathoadrenal systems (both centrally and peripherally) the regulation of water and sodium intake. However, AT 1 receptors are localized not only in areas related to the regulation of autonomic and endocrine control, but also in many other areas of the brain responsible for emotional, sensory and motor functions. For example central Ang II through AT 1 receptors may be a specific brain modulatory factor in the control of the reaction to stress (Mayorov, 2011; Saavedra et al., 2011) . Stress can affect not only the hormonal and cardiovascular system, but also the gastric mucosal integrity and can initiate gastric mucosal damage. A potent, non-peptide AT 1 receptor antagonist with a good penetration to the brain given peripherally inhibited the development of stress-induced gastric ulcers (Armando et al., 2003) . Similarly, in spontaneously hypertensive rats 2 weeks treatment with AT 1 receptor antagonist candesartan (given subcutaneously) resulted in inhibition of stress-induced ulcerations, by protection of gastric mucosal blood flow, decreased sympathoadrenal activation and prevention of the stress-induced inflammatory response of the gastric mucosa (Bregonzio et al, 2003; Saaverda and Benicky, 2007) . Moreover, telmisartan and in a lesser extent candesartan were shown to inhibit indomethacin-and cold restraint-stress induced gastric ulcer formation, gastric acid secretion and the oxidative stress of gastric mucosa, and partial peroxisome proliferator-activated receptor gamma agonistic properties were supposed to play a role in the anti-ulcer action (Morsy et al., 2009 ). In addition the central, anti-stress effect may also contribute to the gastroprotective effect of the angiotensin II AT 1 receptor blocking drugs.
However, data of the literature suggest that not only the blockade but activation of central AT 1 receptor can also elicit gastric mucosal protection, e.g. microinjection of Ang II into the PVN inhibited mucosal injury in gastric ischemia-reperfusion induced ulcer model in a dose-dependent manner. The underlying mechanism is the increase of gastric blood flow, which effect turned to be mediated by central AT 1 receptors (Zhang et al., 2008) . Moreover, reversal of the elevated mucosal level of NF-kappaB during gastric ischemia-reperfusion by Ang II may contribute to the Ang II-induced protection against injury (Zhang et al., 2008) .
Accordingly, also our present findings suggest that activation of central AT 1 receptors may elicit gastric mucosal protection against an acid independent, ethanol-ulcer model via the endocannabinoid system both in rats and mice.
The precise mechanism and site of centrally initiated gastroprotective action has been intensively analyzed. The dorsal vagal complex is likely to have a prominent role in conveying the centrally initiated effect to the periphery. It was shown that both vagotomy and atropine decreased the gastroprotective effects of centrally injected thyrotropin releasing hormone (TRH), adrenomedullin, peptide YY, opioid peptides, clonidine (for reviews see Gyires, 2005; Tache 2012 ), nociceptin, nocistatin and cannabinoids (Shujaa et al., 2009; Zádori et al., 2008) . Pharmacological and biochemical studies have shown that activation of vagal cholinergic pathways stimulates gastric prostaglandin and NO release and the "efferent function" of capsaicin sensitive primary afferent fibers containing CGRP (Kato et al., 1994; Saperas et al., 1995; Yoneda and Tache, 1993) . Also nucleus of the solitary tract (NTS) was hypothesized to be involved in centrally initiated gastroprotective effect of clonidine and opioid peptides (Gyires et al., 2000) .
As the present results show bilateral cervical vagotomy reduced in a significant manner the gastroprotective effect of centrally given Ang II indicating that vagal nerve is likely to be involved in conveying the centrally initiated effect to the periphery. Since atropine also significantly inhibited (but not abolished) the mucosal protective effect of Ang II, the involvement of cholinergic muscarinic receptors in the protective effect is suggested. This assumption is supported by the results of Lenkei et al. (1998) who found high AT 1 messenger RNA expression in the hypothalamic periventricular nucleus, in the paraventricular nucleus, in the NTS and in the area postrema. Others found that Ang II receptors have been detected at all levels of the vagal sensory and motor system (Diz et al., 2002) . The role of the dorsal vagal complex in AT 1 receptor-mediated actions was suggested by the findings, that microinjections of ANG-(1-12) (0.06 mM) into the NTS decreased the mean arterial pressure and heart rate by activation of AT 1 receptors, and bilateral vagotomy abolished this effect (Chitravanshi and Sapru, 2011) . Moreover, microinjection of Ang II into the dorsal motor nucleus of vagus resulted in increased vagal outflow to the heart and GI tract (Diz et al., 1984) . In addition, microinjection of low (femtomolar) doses of Ang II into the dorsal medial region of the NTS produced a transient fall in blood pressure and heart rate in anesthetized rats (Fow et al., 1994; Mosqueda-Garcia et al., 1990; Rettig et al., 1986) , however, higher doses evoked pressor responses (Casto and Phillips, 1986; Luoh and Chan, 1998; Michelini and Bonagamba, 1990) creating a bisphasic dose-response curve. Interestingly, the mucosal protective effect of i.c.v.
injected Ang II proved to be also biphasic, in low (picomolar) doses it induced a pronounced gastroprotective action, however, the effect was decreased when higher doses were given.
Both AT 1 -and CB 1 -receptors were identified in the NTS, in the dorsal motor nucleus of vagus and in the paraventricular nuclei (Castelli et al., 2007; Partosoedarso et al., 2003; Seagard et al., 2004) . On the basis of this findings it may be speculated that AT 1 receptorinduced activation of CB 1 receptors might take place in the dorsal vagal complex, however, whether there is an overlap in expression of CB 1 and AT 1 receptors in this brain area remains to be clarified. Moreover, since both vagotomy and atropine reduced, but did not abolish the protective effect of Ang II, besides vagal nerve additional mechanism -for example the sympathetic nervous system -may also play a role in conveying the centrally initiated action to the gastric mucosa.
In summary, here we showed that Ang II exerted gastroprotective effect injected i.c.v., via activating the endocannabinoid system, since both CB 1 cannabinoid receptor antagonist and inhibitor of DAGL (responsible for the synthesis of 2-AG) decreased the effect of Ang II. 
Highlights:
 Ang II (i.c.v.) induces gastroprotection via a DAGL-dependent mechanism in rats.
 Ang II (i.c.v.) fails to induce gastroprotection in CB1 (-/-) mice.
*Highlights (for review)
